Incretin-based therapies in type 2 diabetes: A review of clinical results
Authors:
- Emanuele BosiEBEmanuele Bosi
- Pietro LucottiPLPietro Lucotti
- Emanuela SetolaESEmanuela Setola
- Lucilla MontiLMLucilla Monti
- Pier Marco PiattiPPPier Marco Piatti
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 82, S102-S107
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Glucolipotoxicity: Fuel Excess and β-Cell DysfunctionEndocrine Reviews, 2008
- Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer HypothesisEndocrine Reviews, 2008
- Cytokines and β-Cell Biology: from Concept to Clinical TranslationEndocrine Reviews, 2007
- β-Cell Failure in Diabetes and Preservation by Clinical TreatmentEndocrine Reviews, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2006
- Achievement of American Diabetes Association Clinical Practice Recommendations Among U.S. Adults With Diabetes, 1999–2002Diabetes Care, 2006
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJournal of Clinical Investigation, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive DiseaseDiabetes, 1995